-+ 0.00%
-+ 0.00%
-+ 0.00%

B. Riley Securities Reiterates Buy on OptimizeRx, Lowers Price Target to $10.5

Benzinga·11/12/2026 15:18:51
Listen to the news
B. Riley Securities analyst Josh Nichols reiterates OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $11 to $10.5.